Search

C. difficile is a major cause of antibiotic-associated gastrointestinal infections. Two C. difficile exotoxins (TcdA and TcdB) are major virulence factors associated with these infections, and chondroitin sulfate proteoglycan 4 (CSPG4) is a potential receptor for TcdB, but its pathophysiological relevance and the molecular details that govern recognition remain unknown. Here, we determine the cryo-EM structure of a TcdB–CSPG4 complex, revealing a unique binding site spatially composed of multiple discontinuous regions across TcdB. Mutations that selectively disrupt CSPG4 binding reduce TcdB toxicity in mice, while CSPG4-knockout mice show reduced damage to colonic tissues during C. difficile infections. We further show that bezlotoxumab, the only FDA approved anti-TcdB antibody, blocks CSPG4 binding via an allosteric mechanism, but it displays low neutralizing potency on many TcdB variants from epidemic hypervirulent strains due to sequence variations in its epitopes. In contrast, a CSPG4-mimicking decoy neutralizes major TcdB variants, suggesting a strategy to develop broad-spectrum therapeutics against TcdB., Chondroitin sulfate proteoglycan 4 (CSPG4) is a potential receptor for C. difficile toxin B (TcdB) during C. difficile infections (CDIs). Here, the cryo-EM structure of a TcdB–CSPG4 complex and CDI mouse models offer insights into CSPG4 role in CDIs and suggest a therapeutic strategy targeting TcdB.

PURPOSE OF REVIEW: Botulinum neurotoxin A (BoNT/A), or Botox, is a popular option for overactive bladder (OAB) and neurogenic bladder (NGB) with or without incontinence. This review aims to discuss the clinical outcomes of BoNT in adult and pediatric bladder conditions, and introduces the potential benefit of novel, engineered neurotoxins beyond BoNT/A. RECENT FINDINGS: A large volume of evidence supports the use of Botox for OAB (to reduce urgency, frequency and incontinence episodes), and for NGB (to decrease incontinence and improve bladder capacity and detrusor pressures). Botox is now also Food & Drug Administration (FDA)-approved for pediatric neurogenic detrusor overactivity. However, urinary retention, diminished response over time and treatment failures are prevalent issues with Botox. Modifying natural BoNTs or forming chimeric toxins are alternatives to BoNT/A that may have higher efficacy and lower side-effect profile. One example is BoNT/B(my-ww). This novel engineered toxin binds to a more commonly expressed synaptotagmin receptor, with potentially more potent paralytic effect and less capacity for systemic diffusion. SUMMARY: Novel engineered neurotoxins may be the next frontier in OAB and NGB therapy.

AIMS We aimed to describe the effectiveness of Onabotulinumtoxin A (Botox) in children with neurogenic bladder (NGB) unresponsive to medical therapy to determine urodynamic parameters predictive of success. METHODS Children receiving Botox for refractory NGB, between 2008 and 2019, from a single academic center, were included in this study. Botox success was defined as improvement of incontinence and/or urodynamic parameters. RESULTS Of 34 patients who received Botox, 13 (38.2%) had a positive response from their first injection, with improvement in capacity by a median of 35% of expected capacity for age compared to only a 9% increase in those who did not respond clinically. When patients were divided into groups by baseline urodynamic parameters, high-pressure (Pdetmax > 20 cm H2 O) patients had significantly greater improvement in compliance compared with low-pressure patients (p = 0.017). Low compliance patients (

INTRODUCTION AND OBJECTIVE:Neurogenic and idiopathic detrusor overactivity (DO) is currently treated with onabotulinumtoxin A (BoNT/A) as third line therapy. In cases of treatment failure, alternat...

Introduction: Inferior vena cava (IVC) thrombosis occurs in

Purpose Men take testosterone (T) boosting supplements to naturally improve T levels. We evaluated the composition and advertised claims of "T boosting" supplements, and supporting published evidence. Materials and methods Fifty "T booster" supplements were evaluated for active ingredients and product claims, discovered via Google search. PubMed was reviewed for any literature supporting the claims, followed by review of Recommended Daily Allowance (RDA) and upper tolerable intake level (UL) for each component. Results Ninety percent of supplements claimed to "boost T", 50% "improve libido", and 48% "feel stronger". One-hundred nine unique components were found, with a mean number of 8.3 per product. On PubMed, 24.8% of supplements had data showing an increase in T with supplementation, 10.1% had data showing a decrease in T, and 18.3% had data showing no change in T. No data were found on 61.5% of supplements on their effect on T. Supplements contained a median 1,291% of the RDA for vitamin B12, 807.6% for vitamin B6, 272% of zinc, 200% of vitamin B5, and 187.5% of vitamin B3. Thirteen products exceeded the US Food and Drug Administration UL of ingredients (zinc, vitamin B3, and magnesium). Conclusions Ninety percent of "T booster" supplements claimed to boost T. However, only 24.8% of these had data to support these claims. A total of 10.1% contained components with data suggesting a negative effect on T. Many had supra-therapeutic doses of vitamins and minerals, occasionally over the UL. Patients should be informed that "T booster" supplements may not have ingredients to support their claims.

INTRODUCTION AND OBJECTIVE:Inferior vena cava (IVC) thrombosis occurs in less than 10% of patients with renal cell carcinoma (RCC). Up to 25% of these cases will require IVC interruption or resecti...

INTRODUCTION AND OBJECTIVE:RPLND is a cornerstone of management in advanced testis cancer. Robotic RPLND (R-RPLND) may be associated with reduced morbidity and length of stay compared to traditiona...

INTRODUCTION AND OBJECTIVES:A 2010 AUA survey of empiric medical therapy (EMT) for male infertility found that 25% of urologists would treat infertile males with testosterone (T) while pursuing a p...

INTRODUCTION AND OBJECTIVES:Many men take over-the-counter “testosterone (T) boosting” supplements in hopes of improving their T naturally. However, these claims may not be supported by evidence. W...

Summary Objective To describe a technique for performing magnetic resonance urogram (MRU) in infants without sedation or anesthesia. Methods Eighteen infants underwent MRU in the absence of sedating medications using a ‘feed and wrap’ technique (FW-MRU). Dynamic contrast enhanced images were obtained. Dynamic radial VIBE and compressed sensing image reconstruction were used to correct for motion artifact. Results Seventeen of the 18 patients had successful FW-MRU. Feed and wrap’ magnetic resonance urogram provided high-quality anatomic and functional renal data. Conclusion Initial experience with FW-MRU demonstrates it to be a promising anesthesia-free modality for obtaining anatomic and functional imaging of the urinary tract in infants.

To evaluate the reasons leading to an extended hospital stay (EHS) in patients undergoing radical cystectomy (RC) with postoperative enhanced recovery after surgery (ERAS) protocol.A total of 509 patients underwent RC and urinary diversion with ERAS between May 2012 and March 2017. The protocol includes no bowel preparation, early feeding, predominantly non-narcotic pain control and µ opioid antagonists. Non-consenting/lost to follow up patients, and those with non-urothelial carcinoma were excluded. We defined EHS as ≥ 5 postoperative days and compared the cohort to those with a LOS of ≤ 4 days. Demographics including modifiable and non-modifiable factors as well as in-house complications as possible contributing factors to EHS was reviewed.There were 279/509 (54.8%) patients had an EHS. Median age was 73 years, 82.4% were male, and 36.6% had a Charlson comorbidity index (CCI) of2. Univariate analysis demonstrated that age65 years, CCI2, increased operative time, anemia requiring transfusion and non-orthotopic diversion were associated with EHS. On multivariate analysis, advanced age, operative time, postop transfusion, CCI2 as well as surgeon specific preferences was associated with EHS. Within EHS patients, 86% stayed due to an in-house complication; ileus (34.3%), anemia requiring transfusion (9.8%), UTIs (9.4%) and atrial fibrillation (8.5%).Advanced age, operative time, postop transfusion, CCI2 and surgeon-specific preferences are associated with an EHS following RC with ERAS. The common causes of EHS are in-house complications, mainly ileus.

Shiga toxins (Stxs) are classic bacterial toxins and major virulence factors of toxigenic Shigella dysenteriae and enterohemorrhagic Escherichia coli (EHEC). These toxins recognize a glycosphingolipid globotriaosylceramide (Gb3/CD77) as their receptor and inhibit protein synthesis in cells by cleaving 28S ribosomal RNA. They are the major cause of life-threatening complications such as hemolytic uremic syndrome (HUS), associated with severe cases of EHEC infection, which is the leading cause of acute kidney injury in children. The threat of Stxs is exacerbated by the lack of toxin inhibitors and effective treatment for HUS. Here, we briefly summarize the Stx structure, subtypes, in vitro and in vivo models, Gb3 expression and HUS, and then introduce recent studies using CRISPR-Cas9-mediated genome-wide screens to identify the host cell factors required for Stx action. We also summarize the latest progress in utilizing and engineering Stx components for biomedical applications.

Summary Introduction/background Metachronous contralateral inguinal hernias (MCH) occur in approximately 10% of pediatric patients following unilateral inguinal hernia repairs (UIHR). Laparoscopic evaluation of the contralateral internal ring is a method of identifying high-risk individuals for prophylactic contralateral exploration and repair. Objective The objective of this study was to assess variation in utilization of diagnostic laparoscopy, and report costs associated with the evaluation of a contralateral patent processus vaginalis during hernia repair in pediatric hospitals. Study design The Pediatric Health Information System database was searched to identify outpatient surgical encounters for pediatric patients with a diagnosis of inguinal hernia during a 1-year period (2014). Records were identified that contained diagnostic codes for unilateral or bilateral inguinal hernia in combination with a procedure code for open hernia repair with or without diagnostic laparoscopy. Results After exclusions there were 3952 hernia repairs performed at 30 hospitals; median age was 4 years (IQR 1–7), 78.8% were male, and 64.9% Caucasian. Three-quarters (76.7%) had UIHR, 8.6% had unilateral repairs with laparoscopy (UIHRL), 12.2% had bilateral inguinal hernia repairs (BIHR), and 2.4% had bilateral repairs with laparoscopy (BIHRL). Where laparoscopy was used, 78% resulted in a unilateral repair and 22% in a bilateral procedure. The percent of patients undergoing laparoscopy varied from 0 to 57% among hospitals, and 0–100% among surgeons. Pediatric surgeons were more than three times more likely to perform a diagnostic laparoscopy compared with pediatric urologists. Median adjusted costs were $2298 (IQR 1659–2955) for UIHR, $2713 (IQR 1873–3409) for UIHRL, $2752 (IQR 2230–3411) for BIHR, and $2783 (IQR 2233–3453) for BIHRL. Median costs varied over two-fold among hospitals ($1310–4434), and over four-fold among surgeons ($948–5040). Discussion Data suggested that Conclusions Variation existed in the use of laparoscopy during inguinal hernia repairs and associated costs within the current sample from children's hospitals in the United States. The additional costs of laparoscopic evaluation must be considered against the clinical utility and therapeutic consequences of identifying individuals with a higher risk of metachronous contralateral inguinal hernia. Summary Table . Characteristics of population and proportion, and cost of hernia repairs with and without diagnostic laparoscopy. Characteristic Total (n = 3.952) Hernia without laparoscopy (n = 3.515) Hernia with diagnostic laparoscopy (n = 437) Laterality: Unilateral 3375 (85.4) 3033 (86.3) 342 (78.3) Bilateral 577 (14.6) 482 (13.7) 95 (21.7) Age, years: Median (IQR) 4 (1–7) 4 (1–7) 2 (0–5) 665 (16.8) 542 (15.4) 123 (28.1) 1–2 917 (23.2) 815 (23.2) 102 (23.3) 3–5 1034 (26.2) 925 (26.3) 109 (24.9) 6–11 869 (22.0) 784 (22.3) 85 (19.5) 12–18 467 (11.8) 449 (12.8) 18 (4.1) Gender: Male 3115 (78.8) 2807 (79.9) 308 (70.5) Female 837 (21.2) 708 (20.1) 129 (29.5) Race/Ethnicity: Caucasian 2565 (64.9) 2264 (64.4) 301 (68.9) Black 658 (16.6) 586 (16.7) 72 (16.5) Other 587 (14.9) 543 (15.4) 44 (10.1) Missing 142 (3.6) 122 (3.5) 20 (4.6) Hispanic 592 (15.0) 544 (15.5) 48 (11.0) Payer type: Public 1849 (46.8) 1658 (47.2) 191 (43.7) Private 1934 (48.9) 1697 (48.3) 237 (54.2) Self/other 169 (4.3) 160 (4.5) 9 (2.1) Surgeon type: Pediatric surgeon 2766 (70.0) 2387 (67.9) 379 (86.7) Pediatric urologist 1186 (30.0) 1128 (32.1) 58 (13.3) Adjusted cost: $2395 ($1735–3071) $2363 ($1718–3024) $2735 ($1990–3425) Table given as median (IQR) or n (%).